{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-016457","form_type":"8-K","ticker":"TNYA","cik":"0001858848","company_name":"Tenaya Therapeutics, Inc.","filed_at":"2022-08-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:57.487636+00:00","generated_at":"2026-06-24T01:35:34.751307+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Tenaya Therapeutics Q2 2022 net loss $28.4M; cash $180.9M; IND submissions on track","bullets":["Net loss $28.4M ($0.69 per share); R&D expense $20.9M; G&A expense $7.7M.","Cash, equivalents and marketable securities $180.9M; expected to fund operations into H2 2023.","IND submissions for TN-201 (MYBPC3) and TN-301 (HDAC6) remain on track for H2 2022.","Manufacturing facility in Union City launched, state-licensed for cGMP drug product at 1000L scale.","Preclinical data presented on TN-401 (PKP2 gene therapy) and novel AAV capsids improving cardiac tropism."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-016457","json":"https://secwatch.observer/filing/0000950170-22-016457.json","markdown":"https://secwatch.observer/filing/0000950170-22-016457.md","text":"https://secwatch.observer/filing/0000950170-22-016457.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022016457/0000950170-22-016457-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1858848/000095017022016457/tnya-20220810.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T01:35:34.751307+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}